Affordable Access

5th Congress of the European Federation of Neurological Societies

Sestre Milosrdnice University hospital and Institute of Clinical Medical Research; [email protected]
Publication Date
  • Medicine


10* news Acta clin Croat 2000; 39:301-304 News 301 World Alzheimer Congress 2000 Washington, DC, July 9-18, 2000 The first ever global conference on Alzheimer’s dis- ease, World Alzheimer Congress 2000, took place in Washington, DC, USA, July 9-18, 2000. Nearly 5,000 of the world’s leading Alzheimer researchers, physicians, healthcare professionals, and other experts gathered for almost ten days to discuss the latest information about Alzheimer research, treatment and caregiving, and strat- egies to eliminate the disease. Alzheimer’s disease affects 12 million people around the world. The number of people with Alzheimer’s disease has been projected to in- crease to 22 million by 2025, and to 45 million by 2050. Alzheimer’s disease is today in focus as a fatal, degenera- tive disease that attacks the brain and results in impaired memory, thinking and behavior. As the disease progresses, it becomes so severe that it interferes with an individual’s daily functioning and eventually results in death. Hosted by the Alzheimer’s Association (USA), Alzheimer’s Disease International and Alzheimer Soci- ety of Canada, World Alzheimer Congress 2000 united four longstanding events with one program: Pivotal Re- search (7th International Conference on Alzheimer’s Dis- ease and Related Disorders), Bridging Research and Care (a new program for physicians aimed at translating latest research achievements to clinical practice), and Creative Care (including 9th National Alzheimer’s Disease Edu- cation Conference, 16th Alzheimer’s Disease Interna- tional, and 22nd Alzheimer Society of Canada Confer- ence). During the Pivotal Research program, some 3,000 international researchers presented their studies on Alzheimer’s disease and other neurodegenerative diseases. Many of these studies offered encouraging news, includ- ing promising results of human safety trials on an Al- zheimer vaccine, favorable outcome of the phase III trial of the drug memantine in people with moderate to severe Alzheimer’s disease, and

There are no comments yet on this publication. Be the first to share your thoughts.